Treatment of adult ADHD and comorbid disorders.
Young
Joel L
JL
Rochester Center for Behavioral Medicine, Rochester, Michigan, USA.
D000328:Adult; D000662:Amphetamines / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use*; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000662:Amphetamines; D000929:Antidepressive Agents, Tricyclic; D000069445:Atomoxetine Hydrochloride; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D011437:Propylamines; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors; C090411:Adderall